An NIH grant will help Cleveland Clinic researchers determine whether the novel dual-action agent can safely lengthen the thrombolytic time window in ischemic stroke and protect against reperfusion injury.
Mobile stroke units have been shown to accelerate patient evaluation and treatment. Now, for the first time, this speedier management has been shown to translate to clinical benefit for patients.
The first reported use of tissue plasminogen activator to treat a pregnant patient for a complicated parapneumonic pleural effusion has a successful outcome.
A report of Cleveland Clinic’s early experience with its mobile stroke unit shows it boosted the likelihood that patients who need tPA will get it in the recommended time window.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A new study shows that when telemedicine is used to connect a hospital-based stroke neurologist with a mobile stroke treatment unit, intervention times are trimmed and technical failures can be kept rare.
Initial experience with one of the nation’s first mobile stroke treatment units shows significant reductions in time to imaging and tPA use for ischemic stroke patients.